ArticleACR open rheumatology2020
The Utility of 18F-FDG PET/CT in Patients With Clinical Suspicion of Polymyalgia Rheumatica and Giant Cell Arteritis: A Prospective, Observational, and Cross-sectional Study.
Article in ACR open rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Musculoskeletal ultrasound findings in GCA with PMR and isolated PMR.Rheumatology advances in practice · 2026Article
- Article
- Positron Emission Tomography/Computed Tomography in Polymyalgia Rheumatica: When and for What-A Critical Review.Diagnostics (Basel, Switzerland) · 2024Review
- The Diagnostic Yield of [Diagnostics (Basel, Switzerland) · 2024Article
- Role and potential ofFrontiers in medicine · 2024Review
- Article
- [Polymyalgia rheumatica in 18-fluorodeoxyglucose-positron-emission-tomography/computed tomography : Improvement in diagnostic accuracy and differentiation from rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2023Article
- Atypical giant cell arteritis presentations diagnosed with FDG-18 whole body PET imaging.BMJ case reports · 2023Article
- Presence of subclinical giant cell arteritis in patients with morning stiffness of duration less than 45 minutes at the time of diagnosis of polymyalgia rheumatica.Reumatologia · 2023Article
- The role of 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and monitoring of large vessel vasculitides - a review article.American journal of nuclear medicine and molecular imaging · 2023Review
- Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients.Journal of clinical medicine · 2022Review
- A Case of Clinical Uncertainty Solved: Giant Cell Arteritis with Polymyalgia Rheumatica Swiftly Diagnosed with Long Axial Field of View PET.Diagnostics (Basel, Switzerland) · 2022Article
- Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica.Rheumatology (Oxford, England) · 2022Article
- Diagnostic accuracy and validation ofFrontiers in medicine · 2022Article
- Imaging Tests in the Early Diagnosis of Giant Cell Arteritis.Journal of clinical medicine · 2021Review
- Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.Scientific reports · 2021Article
- Clinical presentation and treatment response in patients with polymyalgia rheumatica and giant cell arteritis during a 40-week follow-up.Rheumatology advances in practice · 2021Article
- Prevalence of Newly Diagnosed Malignancies in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis, Comparison of 18F-FDG PET/CT Scan with Chest X-ray and Abdominal Ultrasound: Data from a 40 Week Prospective, Exploratory, Single Centre Study.Journal of clinical medicine · 2020Article
- Temporal artery biopsy: A technical guide and review of its importance and indications.Survey of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveTo define the proportions of agreement between fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), clinical diagnosis, and temporal artery biopsy (TAB) in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Furthermore, the association of 18F-FDG PET/CT uptake patterns and clinical presentation of newly diagnosed PMR and GCA was investigated.
methodsEighty patients newly suspected of having PMR, GCA, or concomitant PMR and GCA were included and followed for 40 weeks. Every patient underwent an 18F-FDG PET/CT scan before or within 3 days of initiation of steroids in case of GCA. FDG uptakes in 8 paired articular/periarticular sites and 14 arterial segments were evaluated based on a 4-point visual grading scale.
resultsOf the 80 patients (female: 50 [62.5%]; mean age ± SD: 72.0 ± 7.9), 64 (80.0%) patients were diagnosed with pure PMR, 3 (3.7%) with pure GCA, and 10 (12.5%) with concomitant PMR and GCA. Additionally, three (3.7%) patients were diagnosed with seronegative rheumatoid arthritis during the follow-up period. For the diagnosis of PMR, 18F-FDG PET/CT had a proportion of agreement of 75.3 (64.2-84.4), compared with clinical diagnosis. When comparing findings of 18F-FDG PET/CT with TAB, 18F-FDG PET/CT had a proportion of agreement of 93.0 (84.3-97.7) in all included patients and 69.2 (38.6-90.9) in the subgroup of patients with vasculitis. C-reactive protein was significantly higher in patients with PMR activity on 18F-FDG PET/CT compared with those without 18F-FDG PET/CT activity (P value = 0.006).
conclusions18F-FDG PET/CT is a powerful imaging technique in PMR and GCA that was in good agreement with clinical diagnosis and TAB.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.